ArticleFrontiers in pharmacology2021
Outcomes and Incidence of PF-ILD According to Different Definitions in a Real-World Setting.
Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Prognostic Value of Bronchoalveolar Lavage in Systemic Autoimmune Rheumatic Diseases-Associated Interstitial Lung Disease.Journal of clinical medicine · 2026Article
- e-Lung computed tomography biomarkers are associated with outcomes in fibrotic interstitial lung diseases.ERJ open research · 2026Article
- Predictors of Progressive Fibrosing Interstitial Lung Diseases and Survival in Fibrosing Interstitial Lung Disease-Related Usual Interstitial Pneumonia.Medicina (Kaunas, Lithuania) · 2026Article
- Initiation of antifibrotic treatment in fibrosing interstitial lung disease: is the clock ticking till proven progression?European respiratory review : an official journal of the European Respiratory Society · 2025Review
- CD206 and dust particles are prognostic biomarkers of progressive fibrosing interstitial lung disease associated with air pollutant exposure.Scientific reports · 2025Article
- Disease trajectories in interstitial lung diseases - data from the EXCITING-ILD registry.Respiratory research · 2024Article
- Vascular Contribution to Lung Repair and Fibrosis.American journal of respiratory cell and molecular biology · 2023Review
- Correlation of monocyte counts with clinical outcomes in idiopathic nonspecific interstitial pneumonia.Scientific reports · 2023Article
- Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases.Frontiers in medicine · 2023Article
- Nintedanib for progressive fibrosing interstitial lung disease: how many meet criteria in a UK district general hospital systemic sclerosis cohort?Rheumatology advances in practice · 2023Article
- Reticulation pattern without honeycombing on high-resolution CT is associated with the risk of disease progression in interstitial lung diseases.BMC pulmonary medicine · 2022Article
- Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From aFrontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.